Clinical Research StudyChronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study
Introduction
Both chronic kidney disease and diabetes mellitus are major causes of morbidity and mortality worldwide.1, 2 Several cohort studies have shown that chronic kidney disease is an independent predictor of cardiovascular disease, and that chronic kidney disease progression is associated with an increase in morbidity and mortality.3, 4, 5 Diabetes mellitus affects approximately 40% of people with chronic kidney disease, and is itself a strong risk factor for both all-cause and cardiovascular mortality.3, 6 Moreover, the excess mortality in people with both type 1 and type 2 diabetes mellitus is predominantly attributable to people with diabetes who have chronic kidney disease.7
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, participants with early stages of chronic kidney disease experienced approximately twice as many cardiovascular disease outcomes as those without chronic kidney disease.8 Analyses of these findings also suggested the hypothesis that chronic kidney disease participants may experience greater mortality with tight glycemic control than those without chronic kidney disease, however, the absence of a significant interaction between glycemic control and chronic kidney disease on mortality left this question unresolved. Similar findings have been reported in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study.9 The higher mortality with early chronic kidney disease in the ADVANCE and ACCORD studies occurred in subjects with approximately 8 and 11 years of diabetes mellitus type 2 whose baseline median hemoglobin (Hb)A1c levels were 7.5% and 8.1%, respectively.8, 9
The Outcome Reduction with an Initial Glargine Intervention (ORIGIN trial) of dysglycemic participants with either prediabetes or early type 2 diabetes (of average duration 5 years) reported that basal glargine insulin-mediated normoglycemia had a neutral effect on cardiovascular outcomes.10, 11 In this subgroup analysis we examined the impact of early chronic kidney disease and of insulin glargine, in people with and without early chronic kidney disease, on cardiovascular outcomes in the ORIGIN participants.
Section snippets
Materials and Methods
ORIGIN was a multicenter randomized controlled trial of 12,537 high-risk patients with prediabetes or early diabetes mellitus type 2. It was designed to assess the effect of basal insulin on health outcomes, and the design and the results have been previously reported.10, 11, 12 The median follow-up period was 6.2 years. In brief, subjects of both sexes were recruited, aged 50 years or older, with prediabetes (ie, impaired glucose tolerance or impaired fasting glucose), or type 2 diabetes on
Study Population
Within the ORIGIN cohort, 82% had established diabetes mellitus type 2, 6% had newly diagnosed diabetes mellitus type 2; and 12% had impaired fasting glucose or impaired glucose tolerance.11 Complete renal function data were available in 12,174/12,537 (97.1%) ORIGIN participants, with 4060 (33%) with chronic kidney disease stage 1-3 and 8114 (67%) without chronic kidney disease. Of those with chronic kidney disease, 4.2% had chronic kidney disease 1, 9.6% had chronic kidney disease 2 (13.8%
Discussion
This subgroup analysis of the ORIGIN data clearly identifies both mild (chronic kidney disease 1-2) and moderate chronic kidney disease (stage 3) as significant risk factors for macrovascular outcomes in people with early dysglycemia. Moreover, these results were not impacted by the use of basal insulin glargine compared with standard treatment. The adverse role of mild to moderate chronic kidney disease on macrovascular outcomes are very similar to a previous analysis of the ACCORD trial,
References (24)
- et al.
Global estimates of the prevalence of diabetes for 2010 and 2030
Diabetes Res Clin Pract
(2010) - et al.
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
Kidney Int
(2011) - et al.
Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes
Kidney Int
(2015) - et al.
The continuum of diabetic vascular disease: from macro- to micro
J Am Coll Cardiol
(2009) - et al.
Prevalence of chronic kidney disease in the United States
JAMA
(2007) - et al.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
N Engl J Med
(2004) - et al.
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Lancet
(2010) KDOQI clinical practice guidelines for diabetes and CKD: 2012 update
Am J Kidney Dis
(2012)- et al.
Kidney disease and increased mortality risk in type 2 diabetes
J Am Soc Nephrol
(2013) - et al.
Albuminuria and kidney function independantly predict cardiovascular and renal outcomes in diabetes
J Am Soc Nephrol
(2009)
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
Am Heart J
Basal insulin and cardiovascular and other outcomes in dysglycemia
N Engl J Med
Cited by (0)
Funding: The ORIGIN trial was funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.
Conflicts of Interest: The authors have nothing to declare. HCG is supported by the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He has received research grant support from Sanofi, Lilly, AstraZeneca and Merck, honoraria for speaking from Sanofi, Novo Nordisk, Boehringer Ingelheim, and AstraZeneca, and consulting fees from Sanofi, Lilly, AstraZeneca, Merck, Novo Nordisk, Abbot, Amgen, and Boehringer Ingelheim.
Authorship: All authors had access to the data and a role in writing this manuscript.